Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 40, Issue 1, 2015, Pages 75-86

  Morris, Carrie A ^a   Dueker, Stephen R ^b   Lohstroh, Peter N ^b   Wang, Li Quan ^c   Fang, Xin Ping ^c   Jung, Donald ^d   Lopez Lazaro, Luis ^e   Baker, Mark ^f   Duparc, Stephan ^f   Borghini Fuhrer, Isabelle ^f   Pokorny, Rolf ^e   Shin, Jang Sik ^g   Fleckenstein, Lawrence ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Eckert and Ziegler Vitalea Science   (United States)

^c XENOBIOTIC LABORATORIES INC   (United States)

^d Pharmaceutical Research Services   (United States)

^e Covance Basel Research Unit AG ^*  (Switzerland)

^f Medicines for Malaria Venture   (Switzerland)

^g Shin Poong Pharmaceuticals   (South Korea)

Author keywords

Antimalarial; Mass balance; Metabolism; Pyronaridine

Indexed keywords

ANTIMALARIAL AGENT; NAPHTHYRIDINE DERIVATIVE; PYRONARIDINE;

ADULT; BIOTRANSFORMATION; BLOOD; CHEMISTRY; CLINICAL TRIAL; FECES; HALF LIFE TIME; HUMAN; LIQUID CHROMATOGRAPHY; MALE; METABOLOMICS; MIDDLE AGED; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROCEDURES; SWITZERLAND; TANDEM MASS SPECTROMETRY; URINE;

ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; FECES; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; NAPHTHYRIDINES; SWITZERLAND; TANDEM MASS SPECTROMETRY;

EID: 84894532970     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0182-0     Document Type: Article

References (8)

1. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-Fuhrer I, Rim HJ (2012) Review of pyronaridine anti-malarial properties and product characteristics. Malar J 11:270. doi: 10.1186/1475-2875-11-270
2. Keck BD, Ognibene T, Vogel JS (2010) Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2(3):469-485. doi: 10.4155/bio.10.14
3. Lee J, Son J, Chung SJ, Lee ES, Kim DH (2004) In vitro and in vivo metabolism of pyronaridine characterized by low-energy collision-induced dissociation mass spectrometry with electrospray ionization. J Mass Spectrom 39(9):1036-1043. doi: 10.1002/jms.663
4. Naik H, Wei SY, Schmidt MS, Murry DJ, Fleckenstein L (2007) Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 853(1-2):80-87. doi: 10.1016/j.jchromb.2007.02.054
5. 2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal Chem 75(9):2192-2196. doi: 10.1021/ac026334j
6. Roffey SJ, Obach RS, Gedge JI, Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39(1):17-43. doi: 10.1080/03602530600952172
7. Schulze-König T, Dueker SR, Giacomo J, Suter M, Vogel JS, Synal H-A (2010) BioMICADAS: compact next generation AMS system for pharmaceutical science. Nucl Instrum Methods Phys Res B 268(7):891-894
8. Vogel JS, Love AH (2005) Quantitating isotopic molecular labels with accelerator mass spectrometry. Methods Enzymol 402:402-422. doi: 10.1016/s0076-6879(05)02013-6